Drugs / HPV vaccine
HPV vaccine
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03900572 | Mar 2019 → Apr 2020 | human papilloma virus infection | Shanghai Zerun Biotechnology Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03813940 | Jan → Aug 2019 | anogenital human papillomavirus infection, cervical cancer | Xiamen University | Completed | No outcome recorded |
| Phase 1 | NCT03085381 | Dec 2016 → Oct 2017 | human papilloma virus infection | Shanghai Bovax Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02710851 | Mar 2016 → Dec 2023 | anogenital human papillomavirus infection | Jun Zhang | Unknown | No outcome recorded |
| Phase 2 | NCT02740790 | Sep 2013 → Sep 2015 | human papilloma virus infection | Shanghai Zerun Biotechnology Co.,Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07431502 | May 2026 → Nov 2030 expected | anogenital human papillomavirus infection, cervical squamous intraepithelial neoplasia, penis carcinoma in situ, vulvar neoplasm | Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05291871 | Jun 2022 → Dec 2026 expected | human papilloma virus infection | University of Washington | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02236234 | Jan 2012 → Jan 2013 | infectious disease | University of Sao Paulo | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02994290 | Jan 2017 → Oct 2021 | — | Yale University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01909752 Background | Jul 2013 → Nov 2016 | non-small cell lung carcinoma | UbiVac | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-08-29 | Shanghai Zerun Biotechnology Co.,Ltd | New HPV vaccine from Zerun Bio receives WHO prequalification walvax.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPV Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02710851 ↗ |
| Known as | 9vHPV | “nonavalent HPV (9vHPV) vaccine” NCT07431502 ↗ |
| Known as | 9vHPV vaccine | “The candidate E. coli-produced 9vHPV vaccine has been preliminarily proven to be well tolerated and immunogenic, which encourages further studies in large cohorts with a wider...” PMID 37283969 ↗ Mar 2023 |
| Known as | Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) | “This phase I clinical study was designed to evaluate the safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli)(hereafter called HPV...” NCT03813940 ↗ |
| Modality | Vaccine | “Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations.” NCT01909752 ↗ |
| Route | Intramuscular | “two 0.5-mL intramuscular injection at the time of the first and third vaccinations” NCT01909752 ↗ |